Leveraging systems biology approaches in clinical pharmacology

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 9, 2013, Pages 477-488

  Melas, Ioannis N ^a,b   Kretsos, Kosmas ^c   Alexopoulos, Leonidas G ^a,b  

^a NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^b PROTATONCE LTD   (Greece)

^c UCB PHARMA   (Belgium)

Author keywords

identification of drug mode of action; modeling of signaling pathways; prediction of clinical drug efficacy; systems biology; systems pharmacology

Indexed keywords

DRUG;

CLINICAL PHARMACOLOGY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL MODEL; MACHINE LEARNING; PHARMACEUTICAL ENGINEERING; REVIEW; SYSTEMS BIOLOGY;

IDENTIFICATION OF DRUG MODE OF ACTION; MODELING OF SIGNALING PATHWAYS; PREDICTION OF CLINICAL DRUG EFFICACY; SYSTEMS BIOLOGY; SYSTEMS PHARMACOLOGY;

DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; SYSTEMS BIOLOGY;

EID: 84890571806     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1859     Document Type: Review

References (64)

1. Lalonde RL, Kowalski KG, Hutmacher MM, et al,. Model-based drug development. Clin Pharmacol Ther 2007; 82 (1): 21-32.
2. Tozer TM, Rowland M,. Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy. Lippincott Williams & Wilkins, Baltimore, MD 21201 2006.
3. van der Graaf P, Benson N,. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 2011; 28 (7): 1460-1464.
4. Vicini P, Van Der Graaf PH,. Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clin Pharmacol Ther 2013; 93 (5): 379-381.
5. Yang R, Niepel M, Mitchison TK, Sorger PK,. Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther 2010; 88 (1): 34-38.
6. Ette EI, Williams PJ,. Pharmacometrics: The Science of Quantitative Pharmacology. Wiley-Interscience, New York 2007.
7. Danhof M, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA,. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008; 29 (4): 186-191.
8. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51 (1): 45-73.
9. Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA,. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007; 47 (1): 357-400.
10. Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK,. Physicochemical modelling of cell signalling pathways. Nat Cell Biol 2006; 8 (11): 1195-1203.
11. Ramakrishnan R, DuBois D, Almon R, Pyszczynski N, Jusko W,. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokin Pharmacodyn 2002; 29 (1): 1-24.
12. Kholodenko B, Yaffe MB, Kolch W,. Computational approaches for analyzing information flow in biological networks. Sci Signal 2012; 5 (220): re1 -.
13. Ringner M,. What is principal component analysis? Nat Biotech 2008; 26 (3): 303-304.
14. Janes KA, Kelly JR, Gaudet S, Albeck JG, Sorger PK, Lauffenburger DA,. Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data. J Comput Biol 2004; 11 (4): 544-561.
15. Bansal M, Belcastro V, Ambesi-Impiombato A, di Bernardo D,. How to infer gene networks from expression profiles. Mol Syst Biol 2007; 3: 78.
16. Margolin A, Nemenman I, Basso K, et al,. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 2006; 7 (Suppl 1): 1-15.
17. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP,. Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005; 308 (5721): 523-529.
18. Hartemink AJ,. Reverse engineering gene regulatory networks. Nat Biotech 2005; 23 (5): 554-555.
19. Mahdavi A, Davey RE, Bhola P, Yin T, Zandstra PW,. Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control. PLoS Comput Biol 2007; 3 (7): e130.
20. Hoops S, Sahle S, Gauges R, et al,. COPASI,-a COmplex PAthway SImulator. Bioinformatics 2006; 22 (24): 3067-3074.
21. Klamt S, Saez-Rodriguez J, Gilles E,. Structural and functional analysis of cellular networks with CellNetAnalyzer. BMC Systems Biol 2007; 1 (1): 2.
22. Kauffman SA,. Metabolic stability and epigenesis in randomly constructed genetic nets. J Theor Biol 1969; 22 (3): 437-467.
23. Thakar J, Pilione M, Kirimanjeswara G, Harvill ET, Albert RK,. Modeling systems-level regulation of host immune responses. PLoS Comput Biol 2007; 3 (6): e109.
24. Helikar T, Konvalina J, Heidel J, Rogers JA,. Emergent decision-making in biological signal transduction networks. Proc Natl Acad Sci 2008; 105 (6): 1913-1918.
25. Calzone L, Tournier L, Fourquet S, et al,. Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS Comput Biol 2010; 6 (3): e1000702.
26. Aldridge BB, Saez-Rodriguez J, Muhlich JL, Sorger PK, Lauffenburger DA,. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. Plos Comput Biol 2009; 5 (4): e1000340.
27. Morris MK, Saez-Rodriguez J, Clarke DC, Sorger PK, Lauffenburger DA,. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Comput Biol 2011; 7 (3): e1001099.
28. Saez-Rodriguez J, Alexopoulos LG, Epperlein J, et al,. Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol Syst Biol 2009; 5: 331.
29. Terfve C, Cokelaer T, Henriques D, et al,. CellNOptR: a flexible toolkit to train protein signaling networks to data using multiple logic formalisms. BMC Systems Biol 2012; 6 (1): 133.
30. Mitsos A, Melas IN, Siminelakis P, Chairakaki AD, Saez-Rodriguez J, Alexopoulos LG,. Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. PLoS Comput Biol 2009; 5 (12): e1000591.
31. Melas I, Mitsos A, Messinis D, Weiss T, Alexopoulos L,. Combined logical and data-driven models for linking signalling pathways to cellular response. BMC Systems Biol 2011; 5 (1): 107.
32. Melas IN, Mitsos A, Messinis DE, Weiss TS, Rodriguez J-S, Alexopoulos LG,. Construction of large signaling pathways using an adaptive perturbation approach with phosphoproteomic data. Mol BioSystems 2012; 8 (5): 1571-1584.
33. Kholodenko BN, Kiyatkin A, Bruggeman FJ, Sontag E, Westerhoff HV, Hoek JB,. Untangling the wires: a strategy to trace functional interactions in signaling and gene networks. Proc Natl Acad Sci 2002; 99 (20): 12841-12846.
34. Wolf-Yadlin A, Sevecka M, MacBeath G,. Dissecting protein function and signaling using protein microarrays. Curr Opin Chem Biol 2009; 13 (4): 398-405.
35. Berrade L, Garcia AE, Camarero JA,. Protein microarrays: novel developments and applications. Pharm Res 2011; 28 (7): 1480-1499.
36. Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK,. Networks inferred from biochemical data reveal profound differences in Toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteom 2010; 9 (9): 1849-1865.
37. Perez OD, Nolan GP,. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotech 2002; 20 (2): 155-162.
38. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT,. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010; 70 (17): 6704-6714.
39. Malinowsky K, Wolff C, Ergin B, Berg D, Becker KF,. Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J Cell Physiol 2010; 225 (2): 364-370.
40. Yu X, Schneiderhan-Marra N, Joos TO,. Protein microarrays for personalized medicine. Clin Chem 2010; 56 (3): 376-387.
41. Wulfkuhle JD, Aquino JA, Calvert VS, et al,. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3 (11): 2085-2090.
42. Ihle NT, Byers LA, Kim ES, et al,. Effect of KRAS Oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104 (3): 228-239.
43. Garraway LA, Jänne PA,. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012; 2 (3): 214-226.
44. Xie L, Xie L, Kinnings SL, Bourne PE,. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 2012; 52 (1): 361-379.
45. Gregori-Puigjané E, Setola V, Hert J, et al,. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci 2012; 109 (28): 11178-11183.
46. Iorio F, Bosotti R, Scacheri E, et al,. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci 2010; 107 (33): 14621-14626.
47. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P,. Drug target identification using side-effect similarity. Science 2008; 321 (5886): 263-266.
48. Lamb J,. The connectivity map: a new tool for biomedical research. Nat Rev Cancer 2007; 7 (1): 54-60.
49. Fliri AF, Loging WT, Volkmann RA,. Drug effects viewed from a signal transduction network perspective. J Med Chem 2009; 52 (24): 8038-8046.
50. Bantscheff M, Eberhard D, Abraham Y, et al,. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25 (9): 1035-1044.
51. Bantscheff M, Hopf C, Savitski MM, et al,. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotech 2011; 29 (3): 255-265.
52. Li J, Rix U, Fang B, et al,. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010; 6 (4): 291-299.
53. Kumar R, Blakemore S, Ellis C, et al,. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. BMC Genomics 2010; 11 (1): 419.
54. Kleinberg S, Hripcsak G,. A review of causal inference for biomedical informatics. J Biomed Informat 2011; 44 (6): 1102-1112.
55. Barretina J, Caponigro G, Stransky N, et al,. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483 (7391): 603-307.
56. Yang W, Soares J, Greninger P, et al,. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41 (D1): D955-D961.
57. Wessels JAM, van der Kooij SM, le Cessie S, et al,. Pharmacogenetics Collaborative Research G. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthr Rheum 2007; 56 (6): 1765-1775.
58. Xie X-Q,. Exploiting PubChem for virtual screening. Expert Opin Drug Discov 2010; 5 (12): 1205-1220.
59. Klipp E, Wade RC, Kummer U,. Biochemical network-based drug-target prediction. Curr Opin Biotechnol 2010; 21 (4): 511-516.
60. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T,. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 2011; 7: 501.
61. Kim HU, Sohn SB, Lee SY,. Metabolic network modeling and simulation for drug targeting and discovery. Biotechnol J 2012; 7 (3): 330-342.
62. Hwang D, Lee IY, Yoo H, et al,. A systems approach to prion disease. Mol Syst Biol 2009; 5: 252.
63. Cosgrove BD, Alexopoulos LG, Hang T-C, et al,. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol BioSystems 2010; 6 (7): 1195-1206.
64. Alexopoulos LG, Saez-Rodriguez J, Espelin C,. High throughput protein-based technologies and computational models for drug development, efficacy and toxicity. In Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools, Xu JJ, Ekins S, (eds). Wiley & Sons, Hoboken, New Jersey 2009.